TCG Advisory Services LLC Invests $367,000 in DaVita Inc. (NYSE:DVA)

TCG Advisory Services LLC bought a new position in shares of DaVita Inc. (NYSE:DVA) in the 4th quarter, HoldingsChannel reports. The fund bought 3,500 shares of the company’s stock, valued at approximately $367,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in DVA. Hanseatic Management Services Inc. purchased a new position in shares of DaVita in the third quarter valued at $36,000. GAMMA Investing LLC purchased a new position in shares of DaVita in the fourth quarter valued at $60,000. Tacita Capital Inc purchased a new position in shares of DaVita in the third quarter valued at $118,000. Federated Hermes Inc. grew its position in shares of DaVita by 1,284.4% in the third quarter. Federated Hermes Inc. now owns 1,246 shares of the company’s stock valued at $118,000 after purchasing an additional 1,156 shares in the last quarter. Finally, CENTRAL TRUST Co grew its position in DaVita by 93.3% during the third quarter. CENTRAL TRUST Co now owns 1,448 shares of the company’s stock worth $137,000 after buying an additional 699 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Trading Up 1.6 %

DVA traded up $2.15 during midday trading on Monday, reaching $136.60. 230,122 shares of the company’s stock traded hands, compared to its average volume of 831,713. The firm has a fifty day moving average of $133.71 and a two-hundred day moving average of $113.08. The stock has a market capitalization of $11.98 billion, a price-to-earnings ratio of 15.28, a P/E/G ratio of 1.17 and a beta of 1.04. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $145.04.

DaVita (NYSE:DVA) last posted its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. The firm had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.58 EPS. On average, equities analysts anticipate that DaVita Inc. will post 9.49 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, insider James O. Hearty sold 26,164 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the transaction, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, COO Michael David Staffieri sold 29,488 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the completion of the transaction, the chief operating officer now owns 37,687 shares in the company, valued at $4,515,279.47. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James O. Hearty sold 26,164 shares of DaVita stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the transaction, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,540 shares of company stock worth $16,551,071. Insiders own 1.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Truist Financial boosted their target price on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Barclays initiated coverage on DaVita in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 target price for the company. StockNews.com raised DaVita from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 25th. Finally, UBS Group boosted their target price on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $118.50.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.